Please try another search
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company’s development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Sandeep C. Kulkarni | 41 | - | Co-Founder, CEO & Director |
Clay B. Siegall | 63 | 2023 | Independent Chairman |
Mark D. McDade | 69 | - | Independent Director |
Aaron Kantoff | 38 | - | Independent Director |
Sapna Srivastava | 53 | - | Independent Director |
Parvinder Singh Thiara | 38 | - | Independent Director |
Caley M. Castelein | 53 | - | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review